We regret to inform you that the publisher of this article, Oxford University Press, has removed this article from DeepDyve.

Occasionally, journals transition between publishers. This article may be available on DeepDyve from the journal's new publisher.

Find the current version of this article on DeepDyve

LBA2_PRAfatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
Park, K.; Tan, E.-H.; Zhang, L.; Hirsh, V.; O'Byrne, K.; Boyer, M.; Yang, J.C.-H.; Mok, T.; Kim, M.; Massey, D.; Zazulina, V.; Paz-Ares, L. Annals of Oncology. 2015.
Find this article